BlackRock’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

BlackRock’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-17,373	Closed	-$9K	–	5176
2019 Q4	$9K	Sell	17,373 -148,658	-90%	-$360K	﹤0.01%	4752
2019 Q3	$633K	Sell	166,031 -1,533	-0.9%	-$5.52K	﹤0.01%	4110
2019 Q2	$1.11M	Sell	167,564 -313,617	-65%	-$1.19M	﹤0.01%	3974
2019 Q1	$1.71M	Sell	481,181 -25,266	-5%	-$137K	﹤0.01%	3759
2018 Q4	$2.01M	Buy	506,447 +21,344	+4%	+$273K	﹤0.01%	3662
2018 Q3	$9.58M	Buy	485,103 +153,448	+46%	+$3.88M	﹤0.01%	3250
2018 Q2	$10.5M	Buy	331,655 +160,175	+93%	+$5.77M	﹤0.01%	3214
2018 Q1	$6.34M	Buy	171,480 +50,589	+42%	+$3.33M	﹤0.01%	3326
2017 Q4	$9.55M	Buy	+120,891	New	+$8.95M	﹤0.01%	3168

BlackRock's MLNT Position: Q1 2020 in Review

BlackRock sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q1 2020, closing a stake of 17,373 shares — an estimated $9K sold.

BlackRock first reported a position in MLNT in Q4 2017 and held it in 9 quarters. The position peaked at $10.5M in Q2 2018. 2 funds tracked by Wall St. Rank hold MLNT as of Q1 2020.

BlackRock reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
BlackRock sold 17,373 Melinta Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $9K.
BlackRock first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 9 quarters.
BlackRock's Melinta Therapeutics, Inc. Common Stock position peaked at $10.5M in Q2 2018.
2 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q1 2020.

Based on BlackRock's 13F filing for Q1 2020, filed 1 May 2020.